Ulrike Klein

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
    Ulrike Klein
    Department of Internal Medicine V, University of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Ann Hematol 88:67-71. 2009
  2. ncbi Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
    Ulrike Klein
    Department of Internal Medicine V, Hematology and Oncology, University of Heidelberg, INF 410, 69120, Heidelberg, Germany
    Ann Hematol 90:429-39. 2011
  3. ncbi Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
    Ulrike Klein
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 117:2136-44. 2011

Detail Information

Publications3

  1. ncbi Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
    Ulrike Klein
    Department of Internal Medicine V, University of Heidelberg, INF 410, 69120 Heidelberg, Germany
    Ann Hematol 88:67-71. 2009
    ..Therefore, we propose LMWH should be used in patients being treated with lenalidomide and dexamethasone at least for the first 3 months of treatment until randomized trials have proven the equality of other pharmacological prophylaxis...
  2. ncbi Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
    Ulrike Klein
    Department of Internal Medicine V, Hematology and Oncology, University of Heidelberg, INF 410, 69120, Heidelberg, Germany
    Ann Hematol 90:429-39. 2011
    ..In conclusion, lenalidomide plus dexamethasone is an effective regimen for relapsed or refractory patients with MM complicated by RI with manageable toxicity...
  3. ncbi Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
    Ulrike Klein
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 117:2136-44. 2011
    ..In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)...